NanoViricides (NNVC) Says Topical Drug Candidates for Treatment of Shingles Demonstrated Excellent Inhibition of Causative Virus

NanoViricides Reports Excellent Inhibitory Effects of Its Topical Shingles Treatment Candidates Against VZV in Multiple Cell Culture Studies

SHELTON, Conn., June 6, 2017 /PRNewswire/ -- NanoViricides, Inc., (NYSE MKT: NNVC) (the "Company"), a pioneer in developing anti-viral nanomedicine drugs, reports that its topical drug candidates in development for the treatment of shingles have demonstrated excellent inhibition of the causative virus with practically no cytotoxicity in cell culture assays using multiple cell lines.

Two of the nanoviricide drug candidates in the HerpeCide program demonstrated almost complete inhibition of the varicella-zoster virus (VZV) at the highest drug doses, whereas... More